<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-id journal-id-type="iso-abbrev">Br. J. Cancer</journal-id><journal-title-group><journal-title>British Journal of Cancer</journal-title></journal-title-group><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">11308271</article-id><article-id pub-id-type="pmc">2363901</article-id><article-id pub-id-type="pii">6691749</article-id><article-id pub-id-type="doi">10.1054/bjoc.2001.1749</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>Novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia of chronic disease associated with cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Smith</surname><given-names>R E</given-names><suffix>Jr</suffix></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Jaiyesimi</surname><given-names>I A</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Meza</surname><given-names>L A</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Tchekmedyian</surname><given-names>N S</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Chan</surname><given-names>D</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Griffith</surname><given-names>H</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Brosman</surname><given-names>S</given-names></name><xref ref-type="aff" rid="aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Bukowski</surname><given-names>R</given-names></name><xref ref-type="aff" rid="aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Murdoch</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Rarick</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Saven</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff11">11</xref></contrib><contrib contrib-type="author"><name><surname>Colowick</surname><given-names>A B</given-names></name><xref ref-type="aff" rid="aff12">12</xref></contrib><contrib contrib-type="author"><name><surname>Fleishman</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff13">13</xref></contrib><contrib contrib-type="author"><name><surname>Gayko</surname><given-names>U</given-names></name><xref ref-type="aff" rid="aff14">14</xref></contrib><contrib contrib-type="author"><name><surname>Glaspy</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff15">15</xref></contrib><aff id="aff1">South Carolina Oncology Associates, 1301 Taylor, Suite IA, Columbia, SC 29201, USA</aff><aff id="aff2">William Beaumont Hospital, 3577 West 13 Mile Road, Suite 40 Royal Oak, MI 48073, USA;</aff><aff id="aff3">Southwest Oncology Associates, 443 Heymann Blvd, Suite A, Lafayette, LA 70503, USA;</aff><aff id="aff4">Pacific Shores Medical Group Inc, 1043 Elm Ave, Suite 104 Long Beach, CA 90813-3244, USA</aff><aff id="aff5">Cancer Care Associates Medical Group, 514 North Prospect St, Redondo Beach, CA 90277-3026, USA</aff><aff id="aff6">Memorial Clinic Research Center 520 Lilly Road,NE Building 3, Olympia, WA 98506, USA</aff><aff id="aff7">Pacific Clinical Research, 1260 15<sup>th</sup>Street, Suite 1200, Santa Monica, CA 90404, USA</aff><aff id="aff8">The Cleveland Clinic Foundation, Desk S33, 9500 Euclid Avenue, Cleveland, OH 44195, USA</aff><aff id="aff9">Urology Associates, 7500 Hanover Parkway, Suite 206, Greenbelt, MD 20770, USA</aff><aff id="aff10">Kaiser Permanente Northwest Division, 3600 North Interstate, Portland, OR 97227, USA</aff><aff id="aff11">Scripps Clinic, 10666 North Torrey Pines Road La Jolla, CA 92037, USA</aff><aff id="aff12">Amgen Inc, One Amgen Center Drive, Thousand Oaks, CA 91320-1799, USA</aff><aff id="aff13">Amgen Inc, One Amgen Center Drive, M/S 24-1-C, Thousand Oaks, CA 91320-1799, USA</aff><aff id="aff14">Amgen Inc, One Amgen Center Drive; M/S 24-1-C, Thousand Oaks, CA 91320-1799, USA</aff><aff id="aff15">UCLA School of Medicine, 200 Medical Plaza, Suite 120, Los Angeles, CA 90024, USA</aff></contrib-group><pub-date pub-type="ppub"><month>4</month><year>2001</year></pub-date><volume>84</volume><issue>Suppl 1</issue><fpage>24</fpage><lpage>30</lpage><permissions><copyright-statement>Copyright &#x000a9; 2001 Cancer Research Campaign</copyright-statement><copyright-year>2001</copyright-year><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>Anaemia is a common haematologic disorder in patients with cancer and has a multifactorial aetiology, including the effects of the malignancy itself and residual effects from previous therapy. Novel erythropoiesis stimulating protein (NESP, darbepoetin alfa), a protein with additional sialic acid compared with erythropoietin (EPO), stimulates erythropoiesis by the same mechanism as recombinant human erythropoietin (rHuEPO) but it is biochemically distinct. NESP, with its approximately 3-fold greater serum half-life, can maintain haemoglobin levels as effectively as rHuEPO in anaemic patients with chronic renal failure and do so with less frequent dosing. We investigated the ability of NESP to safely increase haemoglobin levels of anaemic patients with non-myeloid malignancies not receiving chemotherapy. NESP was administered under the supervision of a physician at doses of 0.5, 1.0, 2.25 or 4.5&#x02008;mcg kg<sup>&#x02212;1</sup>wk<sup>&#x02212;1</sup>for a maximum of 12 weeks. This report includes 89 patients completing the study by November 2000. NESP was well tolerated, with no reported dose-limiting toxicities or treatment-related severe adverse events. Increasing doses of NESP corresponded with increased efficacy. The percentage (95&#x00025; confidence interval) of patients responding ranged from 61&#x00025; (42&#x00025;, 77&#x00025;) in the 1.0&#x02008;mcg kg<sup>&#x02212;1</sup>wk<sup>&#x02212;1</sup>group to 83&#x00025; (65&#x00025;, 94&#x00025;) in the 4.5&#x02008;mcg kg<sup>&#x02212;1</sup>wk<sup>&#x02212;1</sup>group. &#x000a9; 2001 Cance Cancer Research Campaign</p></abstract><kwd-group><kwd>anaemia</kwd><kwd>cancer</kwd><kwd>chemotherapy</kwd><kwd>chronic disease</kwd><kwd>darbepoetin alfa</kwd><kwd>erythropoietin</kwd></kwd-group></article-meta></front></article>
